UK Markets closed

Global Generic Drugs Market to Reach US$536.4 Billion by the Year 2027

·22-min read

Abstract: - Global Generic Drugs Market to Reach US$536. 4 Billion by the Year 2027. - Amid the COVID-19 crisis, the global market for Generic Drugs estimated at US$365.

New York, June 23, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Generic Drugs Industry" - https://www.reportlinker.com/p06041415/?utm_source=GNW
9 Billion in the year 2020, is projected to reach a revised size of US$536.4 Billion by 2027, growing at a CAGR of 5.6% over the period 2020-2027.Small-Molecule Generics, one of the segments analyzed in the report, is projected to grow at a 5.2% CAGR to reach US$325.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Biosimilars segment is readjusted to a revised 6.3% CAGR for the next 7-year period. This segment currently accounts for a 37.7% share of the global Generic Drugs market.

- The U.S. Accounts for Over 30.5% of Global Market Size in 2020, While China is Forecast to Grow at a 7.2% CAGR for the Period of 2020-2027

- The Generic Drugs market in the U.S. is estimated at US$111.4 Billion in the year 2020. The country currently accounts for a 30.46% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$97.6 Billion in the year 2027 trailing a CAGR of 7.2% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.8% and 5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR while Rest of European market (as defined in the study) will reach US$97.6 Billion by the year 2027.

- Select Competitors (Total 42 Featured)

  • Fresenius Kabi AG

  • Mylan Pharmaceuticals, Inc.

  • Novartis AG

  • Pfizer, Inc.

  • Teva Pharmaceutical Industries Ltd.




Read the full report: https://www.reportlinker.com/p06041415/?utm_source=GNW

CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
The Race Between the Virus & Vaccines Intensifies. Amidst this
Chaotic Battle, Where is the World Economy Headed in 2021?
EXHIBIT 1: How Fast the World is Vaccinated Will Determine How
Soon the Pandemic Will End: Global Number of Annual COVID-19
Vaccine Doses (In Million) for Years 2020 through 2025 by
Geographic Region/Country
Progress on Vaccinations, Why Should Businesses Care?
These are Times When Questions Abound & Answers Are Few
With IMF?s Upward Revision of Global GDP Forecasts for 2021,
Most Companies Are Bullish About a Global Economic Comeback.
EXHIBIT 2: A Strong 2021 Economic Rebound Based On Pent-Up
Demand Comes as a Relief for Suffering Industries & Markets:
World Economic Growth Projections (Real GDP, Annual % Change)
for 2020 through 2022
How the Healthcare Industry Has & Continues to be Impacted by
the Pandemic & What?s the New Normal?
EXHIBIT 3: With the COVID-19 Pandemic Exposing Global
Healthcare Unpreparedness, There is Increasing Policy Led
Focus on Rebooting Health Systems Worldwide: Current &
Required Healthcare Spending as % of GDP
Impact of COVID-19 Crisis on Generic Drugs Market
Demand for Generic Pain Killers Rises
A Prelude to Generic Drugs
Generic Drugs Market Set for a Rapid Growth
US Dominates, Asia-Pacific to Exhibit the Fastest Growth
India- A Significant Market
Market Restraints
Competition
Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Patent Expiries Set to Widen the Addressable Market for Generic
Drugs
EXHIBIT 4: Patent Expiries of Select Drugs in 2020
EXHIBIT 5: Patent Expiries of Select Drugs in 2021
EXHIBIT 6: Patent Expiries of Select Drugs in 2022
Patent Expiry of Select Major Drugs in the US: 2020-2022
Robust Demand for Pharmaceutical Drugs Drives Demand for
Generic Drugs
Cost Containment Measures Put Focus on Generics
Small Molecule Generics Represent the Dominant Segment
Increasing Demand for Biosimilars, Driven by Patent Expiry of
Major Biopharmaceutical Drugs
Patent Expiries of Major Biopharmaceutical Drugs in the US and
Europe
Progressive Regulatory Framework Accelerates Product Approvals &
Subsequently Market Revenues
Specific Guidelines for Biosimilars in Various Countries with
Year of Publication
Biosimilars Regulatory Agencies in Select Regional Markets
Biosimilar Approvals in the US (as of February 2021)
Biosimilar Approvals in Europe (as of January 2021)
Rising Healthcare Costs Drive Demand for Generic Drugs
EXHIBIT 7: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023
Aging Population to Propel the Demand for Generic Drugs
EXHIBIT 8: Global Aging Population Statistics for the 65+ Age
Group in Million by Geographic Region for the Years 2019,
2025, 2035 and 2050
Rising Prevalence of Chronic Diseases Drive the Demand for
Generic Drugs
EXHIBIT 9: Global Cost of Chronic Diseases (In US$ Billion) for
the Years 2018 and 2030
EXHIBIT 10: Fatalities by Heart Conditions - Estimated
Percentage Breakdown for Cardiovascular Disease, Ischemic
Heart Disease, Stroke, and Others
EXHIBIT 11: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT 12: Number of New Cancer Cases and Deaths (in Million)
by Region for 2018

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Generic Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 2: World Historic Review for Generic Drugs by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 3: World 15-Year Perspective for Generic Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Small-Molecule
Generics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Small-Molecule Generics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Small-Molecule Generics
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Biosimilars by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Biosimilars by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Biosimilars by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Cardiovascular by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Cardiovascular by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Cardiovascular by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Central Nervous
System (CNS) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Central Nervous System
(CNS) by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Central Nervous System
(CNS) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 16: World Current & Future Analysis for Dermatology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Dermatology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for Dermatology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Respiratory by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Respiratory by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Respiratory by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Other Therapeutic
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Other Therapeutic
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Other Therapeutic
Applications by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 28: USA Current & Future Analysis for Generic Drugs by
Type - Small-Molecule Generics and Biosimilars - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 29: USA Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 30: USA 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2012, 2020 & 2027

Table 31: USA Current & Future Analysis for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Generic Drugs by Therapeutic
Application - Cardiovascular, Central Nervous System (CNS),
Dermatology, Oncology, Respiratory and Other Therapeutic
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

CANADA
Table 34: Canada Current & Future Analysis for Generic Drugs by
Type - Small-Molecule Generics and Biosimilars - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 35: Canada Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 36: Canada 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule
Generics and Biosimilars for the Years 2012, 2020 & 2027

Table 37: Canada Current & Future Analysis for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 38: Canada Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 39: Canada 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

JAPAN
Table 40: Japan Current & Future Analysis for Generic Drugs by
Type - Small-Molecule Generics and Biosimilars - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 41: Japan Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 42: Japan 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2012, 2020 & 2027

Table 43: Japan Current & Future Analysis for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 44: Japan Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 45: Japan 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

CHINA
Table 46: China Current & Future Analysis for Generic Drugs by
Type - Small-Molecule Generics and Biosimilars - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 47: China Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 48: China 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2012, 2020 & 2027

Table 49: China Current & Future Analysis for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 50: China Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 51: China 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

EUROPE
Table 52: Europe Current & Future Analysis for Generic Drugs by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 53: Europe Historic Review for Generic Drugs by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 54: Europe 15-Year Perspective for Generic Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

Table 55: Europe Current & Future Analysis for Generic Drugs by
Type - Small-Molecule Generics and Biosimilars - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 56: Europe Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 57: Europe 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule
Generics and Biosimilars for the Years 2012, 2020 & 2027

Table 58: Europe Current & Future Analysis for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 59: Europe Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 60: Europe 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

FRANCE
Table 61: France Current & Future Analysis for Generic Drugs by
Type - Small-Molecule Generics and Biosimilars - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 62: France Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 63: France 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule
Generics and Biosimilars for the Years 2012, 2020 & 2027

Table 64: France Current & Future Analysis for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 65: France Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 66: France 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

GERMANY
Table 67: Germany Current & Future Analysis for Generic Drugs
by Type - Small-Molecule Generics and Biosimilars - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 68: Germany Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 69: Germany 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule
Generics and Biosimilars for the Years 2012, 2020 & 2027

Table 70: Germany Current & Future Analysis for Generic Drugs
by Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 71: Germany Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 72: Germany 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

ITALY
Table 73: Italy Current & Future Analysis for Generic Drugs by
Type - Small-Molecule Generics and Biosimilars - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 74: Italy Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 75: Italy 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2012, 2020 & 2027

Table 76: Italy Current & Future Analysis for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 77: Italy Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 78: Italy 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 79: UK Current & Future Analysis for Generic Drugs by
Type - Small-Molecule Generics and Biosimilars - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 80: UK Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 81: UK 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2012, 2020 & 2027

Table 82: UK Current & Future Analysis for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 83: UK Historic Review for Generic Drugs by Therapeutic
Application - Cardiovascular, Central Nervous System (CNS),
Dermatology, Oncology, Respiratory and Other Therapeutic
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 84: UK 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

SPAIN
Table 85: Spain Current & Future Analysis for Generic Drugs by
Type - Small-Molecule Generics and Biosimilars - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 86: Spain Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 87: Spain 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2012, 2020 & 2027

Table 88: Spain Current & Future Analysis for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 89: Spain Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 90: Spain 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

RUSSIA
Table 91: Russia Current & Future Analysis for Generic Drugs by
Type - Small-Molecule Generics and Biosimilars - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 92: Russia Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 93: Russia 15-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule
Generics and Biosimilars for the Years 2012, 2020 & 2027

Table 94: Russia Current & Future Analysis for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 95: Russia Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 96: Russia 15-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

REST OF EUROPE
Table 97: Rest of Europe Current & Future Analysis for Generic
Drugs by Type - Small-Molecule Generics and Biosimilars -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 98: Rest of Europe Historic Review for Generic Drugs by
Type - Small-Molecule Generics and Biosimilars Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 99: Rest of Europe 15-Year Perspective for Generic Drugs
by Type - Percentage Breakdown of Value Sales for
Small-Molecule Generics and Biosimilars for the Years 2012,
2020 & 2027

Table 100: Rest of Europe Current & Future Analysis for Generic
Drugs by Therapeutic Application - Cardiovascular, Central
Nervous System (CNS), Dermatology, Oncology, Respiratory and
Other Therapeutic Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 101: Rest of Europe Historic Review f
Read the full report: https://www.reportlinker.com/p06041415/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting